Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Neoplasm Metastasis 1Multiple Myeloma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Diphosphonates × Clear all
NCT07043608 2026-05-01

ZAMBONI

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01215344 2018-05-15

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
36 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡